<DOC>
	<DOCNO>NCT02734446</DOCNO>
	<brief_summary>The purpose project evaluate randomized clinical trial , double-blind , control , effect dietary supplement contain Lactobacillus reuteri DSM 17938 vitamin D3 reduce bronchial inflammation improve asthma control patient child mild / moderate persistent asthma .</brief_summary>
	<brief_title>To Evaluate Efficacy Supplementation With L. Reuteri + Vit . D3 Asthmatic Children</brief_title>
	<detailed_description>To evaluate supplementation three month Lactobacillus reuteri DSM 17938 ( 108 CFU ) + Vitamin D3 ( 400 IU ) result reduction degree allergic bronchial inflammation , measure Fractional exhale nitric oxide ( FeNO ) series marker bronchial inflammation ( measure 'beginning end treatment exhale condensate ) : Interleukin 2 ( IL-2 ) ; Interleukin 4 ( IL-4 ) ; Interleukin 10 ( IL-10 ) ; Interferon γ ( IFN-γ ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Patients age 6 14 year old , sexes Diagnosis mild / moderate persistent asthma ( GINA step 2/3 ) Allergy mite ( Dermatophagoides farinae pteronyssinus + + + / + + + + ) Levels vitamin 25 ( OH ) D &lt; 30 ng / ml Signature inform consent one parent legal representative Cardiovascular disease systemic anatomical abnormality Other respiratory disease Taking probiotic / prebiotics previous 2 week Taking vitamin D systemic corticosteroid within 4 week Participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Bronchial Inflammation</keyword>
	<keyword>Asthma</keyword>
	<keyword>Childhood Asthma Control Test ( C-ACT )</keyword>
	<keyword>Asthma Exacerbations</keyword>
</DOC>